Novavax Amends 2024 Proxy Statement

TL;DR

NOVAVAX filed an amendment to its proxy statement for the 2024 annual meeting. Check for updates.

AI Summary

Novavax, Inc. filed an amendment to its proxy statement on June 5, 2024, for its 2024 Annual Meeting of Stockholders. This filing, an amendment to the April 29, 2024 proxy statement, provides updated information for the meeting. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing provides updated information to shareholders regarding the upcoming annual meeting, which is crucial for their participation in corporate governance decisions.

Risk Assessment

Risk Level: low — This is a routine amendment to a proxy statement, not indicating new material risks or significant changes in company operations.

Key Players & Entities

• NOVAVAX INC (company) — Registrant
• 2024 Annual Meeting of Stockholders (event) — Subject of the proxy statement
• April 29, 2024 (date) — Date of original proxy statement
• June 5, 2024 (date) — Date of filing amendment

FAQ

Key Financial Figures

• $1,500,000 — Amended 2015 Stock Plan, may not exceed $1,500,000 in the case of the chairman of the Boar
• $1,000,000 — e case of the chairman of the Board and $1,000,000 in the case of any other non-employee d

Filing Documents

• tm2416428d1_defa14a.htm (DEFA14A) — 14KB
• 0001104659-24-068426.txt ( ) — 15KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 NOVAVAX, INC. (Name of registrant as specified in its charter) (Name of person(s) filing proxy statement, if other than the registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. AMENDMENT TO PROXY STATEMENT DATED APRIL 29, 2024, FOR THE NOVAVAX, INC. 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 13, 2024. EXPLANATORY NOTE This Amendment No. 1 amends the Definitive Proxy to be held on June 13, 2024 (the “ Annual Meeting ”). This Amendment No. 1 is being filed for the sole purpose of clarifying an immaterial aspect of the Amended and Restated 2015 Stock Incentive Plan in connection with “Proposal 3 – Amendment and Restatement of the 2015 Stock Plan.” Except as described in this Amendment No. 1, none of the items or information presented in the 2024 Definitive Proxy Statement is affected by this Amendment No. 1. This Amendment No. 1 does not provide all of the information that is important to your voting decisions at the Annual Meeting, and the 2024 Definitive Proxy Proxy Statement. Item 1 The below language is hereby added to page 78 of the 2024 Definitive Proxy Statement, under the sub-heading “Non-Employee Director Limits”: The aggregate value of all compensation paid or granted to a non-employee director solely for services to the Board in any year, including awards under the Amended 2015 Stock Plan and cash fees or other compensation paid outside the Amended 2015 Stock Plan, may not exceed $1,500,000 in the case of the chairman of the Board and $1,000,000 in the case of any other non-employee director (or $1,500,000 with respect to the year in which a non-employee director commences service on the Board). These limitations do not apply to any compensation granted or paid to a non-employee director for his or her services to the Company other than as a non-employee director, including as a consultant or advisor. The Amended 2015 Stock Plan otherwise eliminates the individual limits on awards granted to any individual in any year under Section 4(c) of the 2015 Stock Plan (previously 500,000 shares of common stock subject to stock options, 500,000 shares of common stock subject to SARs, and 250,000 shares subject to stock awards other than stock options or SARs).

View Full Filing

View this DEFA14A filing on SEC EDGAR